Dolac, 30 mg/ml 1 ml 10 pcs

Pharmacological action – analgesic, antiaggregative, antipyretic, anti-inflammatory.

Inhibits cyclooxygenase (mainly in peripheral tissues), inhibits the synthesis of GH – modulators of pain sensitivity, thermoregulation and inflammation.

The analgesic effect develops after 1/2 hour, reaches its maximum after 1-2 hours and lasts 4-6 hours. It inhibits platelet aggregation, reduces the concentration of thromboxane and increases bleeding time.

Indications

Pain syndrome of moderate and severe intensity (short relief, mainly in the postoperative period).

Pharmacological effect

Pharmacological action – analgesic, antiaggregation, antipyretic, anti-inflammatory.

Inhibits cyclooxygenase (mainly in peripheral tissues), inhibits the synthesis of PG – modulators of pain sensitivity, thermoregulation and inflammation.

The analgesic effect develops after 1/2 hour, reaches a maximum after 1–2 hours and lasts 4–6 hours. Inhibits platelet aggregation, reduces the concentration of thromboxane and increases bleeding time.

Special instructions

Dolak solution for injection is incompatible in the same syringe with promethazine, hydroxyzine (a precipitate forms); compatible with saline solution, 5% glucose solution, Ringer’s solution, Plasmalit solution, as well as with infusion solutions containing aminophylline, lidocaine hydrochloride, dopamine hydrochloride, short-acting human insulin and heparin sodium salt.

Active ingredient

Ketorolac

Composition

1 ml of solution for intravenous and intramuscular administration contains:

active substance – ketorolac tromethamine 30 mg;

excipients – sodium chloride,

disodium edetate,

propylene glycol,

buffer solution (potassium dihydrogen phosphate, sodium hydroxide, water for injection),

sodium hydroxide and hydrochloric acid – to adjust pH,

water for injections.

Contraindications

Hypersensitivity incl. etc. NSAIDs, peptic ulcer of the stomach and duodenum in the acute stage, a history of ulcers, perforation or gastrointestinal bleeding, moderate and severe renal failure, the risk of its development with hypovolemia or dehydration, hemorrhagic stroke, conditions with a high risk of bleeding or incomplete hemostasis, the preoperative period and during surgery (due to the high risk of bleeding); simultaneous use of other NSAIDs, incl. aspirin, as well as pentoxifylline; pregnancy, childbirth, breastfeeding, age up to 16 years.

Side Effects

From the nervous system and sensory organs: headache, dizziness, nervousness, tremor, impaired ability to concentrate, asthenia, depression, hallucinations, paresthesia, convulsions; disturbance of taste and vision.

From the cardiovascular system and blood (hematopoiesis, hemostasis): decreased or increased blood pressure, palpitations, anemia, eosinophilia, thrombocytopenia, leukopenia.

From the respiratory system: dyspnea, cough, bronchospasm, bronchial asthma, pulmonary edema.

From the gastrointestinal tract: dry mouth, stomatitis, nausea, vomiting, feeling of fullness in the stomach, flatulence, constipation or diarrhea, dyspepsia, gastritis, peptic ulcers, rectal bleeding, melena.

From the genitourinary system: hematuria, glomerulonephritis, nephrotoxic syndrome, acute renal failure, urinary retention, polyuria, frequent urination.

From the skin: pallor of the skin, itching, rash (including hemorrhagic), pain at the injection site.

Allergic reactions: anaphylaxis, anaphylactoid reaction, swelling of the larynx, swelling of the tongue.

Other: liver dysfunction.

Interaction

Acetylsalicylic acid and other NSAIDs mutually increase the risk of developing severe side effects.

Pentoxifylline and substances that affect hemostasis (warfarin, heparin, dextrans) increase the likelihood of bleeding.

Probenecid reduces plasma Cl and volume of distribution, increases plasma concentration, and T1/2. Reduces the diuretic effect of furosemide. Concomitant use with ACE inhibitors may increase the risk of renal dysfunction.

Storage conditions

In a dry place, protected from light, at a temperature of 15–25 °C

Shelf life

2 years

Manufacturer

Cadila Pharmaceuticals Ltd, India